Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Gut richness and diversity decrease significantly by week 5 of chemoradiotherapy. by Molly B. El Alam (10231830)

MMP-2 production is decreased following ALK5 inhibition. by Rebecca A. Scott (488956)

Inhibition of ABCG2 decreases SP cells, but not sphere-forming ability. by Noriko Kawai (6694010)

Subjects:

Table 5_Road transportation is associated with decreased intestinal motility in horses.docx by Sharanne L. Raidal (3097719)

“…Signalment and past travel history were not predictive of intestinal motility, but horses with unknown or no prior travel history (mean 12.8, 95%CI 8.2-17.4 nmol/L) had higher cortisol concentrations prior to departure than horses known to have travelled previously (7.9, 5.8−9.9 nmol/L, p = 0.023).…”

Overexpression of mC4 decreased membrane capacitance without altering overall excitability. by Ashley L. Comer (8299128)

Decreasing mean transistor size since 2000. by David Burg (8209752)

Comparison of mean differences in temperature decreases. by Hans-Jörg Gillmann (8460585)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects: